REMaST® recognized as an orphan drug for acute spinal injuries

The advanced cell therapy REMaST® developed by Hemera has been granted orphan drug designation by the European Commission for the treatment of acute spinal cord injuries. This important recognition underlines the importance of the results obtained so far and the high potential for treatment for patients who have suffered an acute spinal injury and are living in a highly disabling condition without a therapeutic alternative.

The designation of Orphan Medicinal Product (ODD) paves the way for an accelerated path in the coming years to give patients back a concrete perspective of autonomy and Hemera will be supported by the European Medicines Agency (EMA) in the next steps towards the authorization marketing with market exclusivity.

We are happy to share this fundamental stage in our growth, thanking all the extraordinary team who work every day with great skill and passion to bring REMaST® therapy to the patient’s bed as soon as possible.